SCHEMBL1028526

SCHEMBL1028526

CC(=O)O[C@H]1CCC[C@@H]1N1C(=O)C=CC1=O

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 7/20 0.47
CHRM1 P11229 5/20 0.47
CHRM4 P08173 4/20 0.47
CHRM3 P20309 4/20 0.47
SLC18A3 Q16572 2/20 0.46
MEN1 O00255 2/20 0.38
CYP2D6 P10635 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1026256 0.83 CHRM1 (0.44) CHRM2CHRM1CHRM4CHRM3SLC18A3
SCHEMBL1028614 0.83 CHRM2 (0.35) CHRM2CHRM1CHRM4CHRM3SLC18A3
SCHEMBL1028701 0.83 CHRM2 (0.51) CHRM2CHRM1CHRM4CHRM3SLC18A3
SCHEMBL1026433 0.83 ALDH1A1 (0.34) CHRM2CHRM1CHRM4CHRM3SLC18A3
SCHEMBL1027856 0.82 NTMT1 (0.36) CHRM2CHRM1CHRM4CHRM3SLC18A3
SCHEMBL1026369 0.80 CYP3A4 (0.36) CHRM2CHRM1CHRM4CHRM3SLC18A3
SCHEMBL1028275 0.80 SLC18A3 (0.51) CHRM2CHRM1CHRM4CHRM3SLC18A3
SCHEMBL1027822 0.79 CHRM2 (0.39) CHRM2CHRM1CHRM4CHRM3SLC18A3
SCHEMBL1028431 0.79 EPHX1 (0.45) CHRM2CHRM1CHRM4CHRM3SLC18A3
SCHEMBL1027547 0.79 ALDH1A1 (0.35) SLC18A3CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479669-B1 Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography TOSOH CORP (JP) 2011-01-19 EP disclosed
US-7645889-B2 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2010-01-12 US disclosed
US-20080230482-A1 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2008-09-25 US disclosed
US-7381742-B2 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2008-06-03 US disclosed
US-20070131616-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2007-06-14 US disclosed
US-7186750-B2 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2007-03-06 US disclosed
US-20040235937-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2004-11-25 US disclosed
EP-1479669-A1 Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography Tosoh Corporation (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080230482-A1 Optically active polymaleimide derivatives and process for their production CYBA, COASY, MEP1B CHRM2 2486/4885CHRM1 2236/4885CHRM4 2831/4885
US-20040235937-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them MACF1, MEP1B, CYBA CHRM2 2296/4885CHRM1 1696/4885CHRM4 2742/4885
US-20070131616-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them MACF1, MEP1B, ACMSD CHRM2 2443/4885CHRM1 2124/4885CHRM4 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.